TAT	Targeted alpha therapy
mCRPC	metastatic castration-resistant prostate cancer
[225Ac]Ac-PSMA	actinium-225-labelled prostate-specific membrane antigen
LET	linear energy transfer
RLT	radioligand therapy
Lu-177	lutetium-177
PSA	prostate-specific antigen
ADT	androgen deprivation therapy
PFS	progression-free survival
RBE	relative biological effectiveness
ECOG	Eastern Cooperative Oncology Group
PCWG3	Prostate Cancer Clinical Trials Working Group 3
mHSPC	hormone-sensitive metastatic prostate cancer
TV	tumour volume
TL-PSMA	Total lesion PSMA
TLG	total lesion glycolysis
OS	overall survival
Th-229	Thorium-229
RCTs	Randomised Controlled Trials
t-MDS	therapy-related myelodysplastic syndromes
EMA	European Medicines Agency
FDA	Food and Drug Administration
IAEA	International Atomic Energy Agency
PARP	poly (ADP-ribose) polymerase